{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:33:27Z","timestamp":1790253207010,"version":"4.1.0"},"reference-count":148,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Wroclaw Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Psoriasis is a chronic, immune-mediated inflammatory skin disease requiring effective long-term systemic treatment. Current options, including using conventional small molecules and biological therapies, are limited by adverse events, suboptimal efficacy, or poor adherence due to inconvenient administration. This highlights an unmet need for safe, convenient, and effective oral self-administered dosage form therapies aligned with patient preferences. This review evaluates the mechanism, safety, and efficacy of next-generation tyrosine kinase 2 (TYK2) inhibitors and compares them to currently available therapeutic options. The pathogenesis of psoriasis is driven by chronic systemic inflammation mediated by the interleukin-23 (IL-23)\/Th17\/interleukin-17 (IL-17) axis. Selective TYK2 inhibitors, such as deucravacitinib, envudeucitinib, and zasocitinib, act through a unique allosteric mechanism by binding to the regulatory pseudokinase domain (JH2) rather than the enzyme\u2019s catalytic domain. This enables highly selective suppression of IL-23-mediated inflammation while mitigating systemic toxicity seen with nonselective Janus kinase (JAK) inhibitors. Clinical trials (POETYK PSO-1 and PSO-2) and long-term extension studies demonstrate that deucravacitinib provides superior efficacy compared to the first-generation oral small molecule apremilast, with high and sustained response rates. It maintains durable efficacy for up to four years in patients with moderate to severe plaque psoriasis and shows a stable long-term safety profile, with low incidence of major adverse cardiovascular events (MACEs), venous thromboembolism (VTE), serious infections, and malignancies. Selective TYK2 inhibition bridges the therapeutic gap, providing an optimal balance of efficacy and oral convenience. With the potential to improve patient adherence and quality of life, these agents represent a promising option to become a first-line oral systemic therapy for psoriasis.<\/jats:p>","DOI":"10.3390\/pharmaceutics18030347","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:44:52Z","timestamp":1773229492000},"page":"347","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["From Convenience to Clinical Efficacy: Selective TYK2 Inhibition in Psoriasis and the Evolving Role of Next-Generation Oral Targeted Therapies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5660-2143","authenticated-orcid":false,"given":"Klara","family":"Andrzejczak","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, Wybrzeze L. Pasteura 1, 50-367 Wroclaw, Poland"},{"name":"University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Sternak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, Wybrzeze L. Pasteura 1, 50-367 Wroclaw, Poland"},{"name":"University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktor","family":"Witkowski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroclaw Medical University, Wybrzeze L. Pasteura 1, 50-367 Wroclaw, Poland"},{"name":"University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0970-6344","authenticated-orcid":false,"given":"Bo\u017cena","family":"Karolewicz","sequence":"additional","affiliation":[{"name":"Department of Drug Form Technology, Wroclaw Medical University, Borowska 211 A, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Ponikowska","sequence":"additional","affiliation":[{"name":"University Centre of General Dermatology and Oncodermatology, Wroclaw Medical University, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A Systematic Review of Worldwide Epidemiology of Psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","unstructured":"Mehta, S., and Sathe, N.C. (2025). Plaque Psoriasis, StatPearls."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"J. Am. Med. Assoc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and Comorbid Diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1111\/jdv.16273","article-title":"The Role of the Interleukin-23\/Th17 Pathway in Cardiometabolic Comorbidity Associated with Psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Musta\u021b\u0103, M.-L., Neagoe, C.-D., R\u0103dulescu, V.-M., Dragne, I.-G., C\u00eempeanu, R.-C., Radu, L., Ahri\u021bculesei, R.-V., For\u021bofoiu, D., Predoi, M.-C., and Iano\u0219i, S.-L. (2025). Association Between Systemic Inflammation, Metabolic Syndrome and Quality of Life in Psoriasis Patients. Life, 15.","DOI":"10.20944\/preprints202501.0009.v1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis of Observational Studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_8","first-page":"81","article-title":"Skin Inflammation, Systemic Inflammation, and Cardiovascular Disease in Psoriasis","volume":"161","author":"Svedbom","year":"2025","journal-title":"J. Am. Med. Assoc. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e3576","DOI":"10.1097\/MD.0000000000003576","article-title":"Association Between Psoriasis and Subclinical Atherosclerosis: A Meta-Analysis","volume":"95","author":"Fang","year":"2016","journal-title":"Medicine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1468-3083.2009.03564.x","article-title":"Cardiovascular Risk Factors in Patients with Plaque Psoriasis: A Systematic Review of Epidemiological Studies","volume":"24","author":"Prey","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-025-00630-5","article-title":"Psoriasis","volume":"11","author":"Armstrong","year":"2025","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/nutd.2012.26","article-title":"The Association between Psoriasis and Obesity: A Systematic Review and Meta-Analysis of Observational Studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr. Diabetes"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cipolla, S., Catapano, P., Bonamico, A.F., De Santis, V., Murolo, R., Romano, F., Volpicelli, A., Perris, F., Lo Schiavo, A., and Fabrazzo, M. (2024). Factors Associated with Anxiety, Depression, and Quality of Life in Patients with Psoriasis: A Cross-Sectional Study. Brain Sci., 14.","DOI":"10.3390\/brainsci14090865"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ghezzi, G., Costanzo, A., and Borroni, R.G. (2024). Health-Related Quality of Life in Psoriasis: Literature Review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13164623"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12955-023-02162-6","article-title":"Development and Validation of a Psoriasis Treatment Acceptability Measure through Group Concept Mapping","volume":"21","author":"Hudgens","year":"2023","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the Systemic Treatment of Psoriasis Vulgaris\u2014Part 1: Treatment and Monitoring Recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/24755303241253200","article-title":"Patients\u2019 Preferences Regarding Modes of Systemic Psoriasis Treatment\u2014A Qualitative Study","volume":"9","author":"Zaino","year":"2024","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.36469\/9817","article-title":"Relative Importance of Mode of Administration in Treatment Preferences among Plaque Psoriasis Patients in the United States","volume":"4","author":"Feldman","year":"2017","journal-title":"J. Health Econ. Outcomes Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.2147\/PPA.S117006","article-title":"Adherence, Satisfaction and Preferences for Treatment in Patients with Psoriasis in the European Union: A Systematic Review of the Literature","volume":"10","author":"Rivera","year":"2016","journal-title":"Patient Prefer. Adherence"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/09546634.2011.607425","article-title":"Factors Affecting Adherence to Treatment of Psoriasis: Comparing Biologic Therapy to Other Modalities","volume":"24","author":"Chan","year":"2013","journal-title":"J. Dermatolog. Treat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/17460441.2023.2246880","article-title":"The Preclinical Discovery and Development of Deucravacitinib for the Treatment of Psoriasis","volume":"18","author":"Coscarella","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40257-017-0302-0","article-title":"Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis","volume":"19","author":"Torres","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2217\/imt-2023-0343","article-title":"Adherence, Persistence and Treatment Switching in Psoriasis","volume":"16","author":"Santoleri","year":"2024","journal-title":"Immunotherapy"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Piragine, E., Petri, D., Martelli, A., Janowska, A., Dini, V., Romanelli, M., Calderone, V., and Lucenteforte, E. (2022). Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061506"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s13555-023-01089-6","article-title":"Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey","volume":"14","author":"Armstrong","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","article-title":"Treatment Preferences and Treatment Satisfaction among Psoriasis Patients: A Systematic Review","volume":"310","author":"Florek","year":"2018","journal-title":"Arch. Dermatol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-Week, Randomized, Double-Blinded, Placebo-Controlled Phase 3 POETYK PSO-1 Trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/jdv.16684","article-title":"Practical Recommendations for Systemic Treatment in Psoriasis According to Age, Pregnancy, Metabolic Syndrome, Mental Health, Psoriasis Subtype and Treatment History (BETA-PSO: Belgian Evidence-Based Treatment Advice in Psoriasis; Part 1)","volume":"34","author":"Lambert","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_30","first-page":"258","article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-Analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"J. Am. Med. Assoc. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjd.12663","article-title":"Efficacy and Safety of Systemic Treatments for Moderate-to-Severe Psoriasis: Meta-Analysis of Randomized Controlled Trials","volume":"170","author":"Schmitt","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_32","first-page":"CD011535","article-title":"Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta-Analysis","volume":"7","author":"Sbidian","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-017-0328-3","article-title":"Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?","volume":"19","author":"Amin","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjd.19325","article-title":"Comparing the Efficacy and Tolerability of Biologic Therapies in Psoriasis: An Updated Network Meta-Analysis","volume":"183","author":"Mahil","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jdv.15879","article-title":"Biologic Therapies Targeting the Interleukin (IL)-23\/IL-17 Immune Axis for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis","volume":"34","author":"Erichsen","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.intimp.2018.06.020","article-title":"Efficacy and Safety of Biologics Targeting IL-17 and IL-23 in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"62","author":"Cui","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1080\/09546634.2017.1422591","article-title":"A Systematic Review and Meta-Analysis of the Efficacy and Safety of the Interleukin (IL)-12\/23 and IL-17 Inhibitors Ustekinumab, Secukinumab, Ixekizumab, Brodalumab, Guselkumab and Tildrakizumab for the Treatment of Moderate to Severe Plaque Psoriasis","volume":"29","author":"Bilal","year":"2018","journal-title":"J. Dermatolog. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","article-title":"Bimekizumab for Patients with Moderate to Severe Plaque Psoriasis: 60-Week Results from BE ABLE 2, a Randomized, Double-Blinded, Placebo-Controlled, Phase 2b Extension Study","volume":"83","author":"Blauvelt","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jdv.14015","article-title":"The Efficacy and Safety of Apremilast, Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis: 52-Week Results from a Phase IIIb, Randomized, Placebo-Controlled Trial (LIBERATE)","volume":"31","author":"Reich","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an Oral Phosphodiesterase 4 (PDE4) Inhibitor, in Patients with Moderate to Severe Plaque Psoriasis: Results of a Phase III, Randomized, Controlled Trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jaad.2020.01.072","article-title":"Efficacy and Safety of Apremilast in Patients with Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study","volume":"83","author":"Lebwohl","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5114\/ada.2022.119081","article-title":"Efficacy of Apremilast for Psoriasis: A Meta-Analysis of Randomized Controlled Studies","volume":"40","author":"Liu","year":"2023","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_44","first-page":"801","article-title":"Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study","volume":"16","author":"Strober","year":"2017","journal-title":"J. Drugs Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Difficult-to-Treat Nail and Scalp Psoriasis: Results of 2 Phase III Randomized, Controlled Trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-Term Safety and Tolerability of Apremilast in Patients with Psoriasis: Pooled Safety Analysis for \u2265156 Weeks from 2 Phase 3, Randomized, Controlled Trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1111\/jdv.16439","article-title":"Real-World Effectiveness and Safety of Apremilast in Psoriasis at 52 Weeks: A Retrospective, Observational, Multicentre Study by the Spanish Psoriasis Group","volume":"34","author":"Armesto","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Dragotto, M., D\u2019Onghia, M., Trovato, E., Tognetti, L., Rubegni, P., and Calabrese, L. (2024). Therapeutic Potential of Targeting the JAK\/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition. J. Clin. Med., 13.","DOI":"10.3390\/jcm13113091"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Garc\u00eda, F., G\u00f3mez-Arias, P.J., Montilla-L\u00f3pez, A., Hern\u00e1ndez-Parada, J., Sanz-Cabanillas, J.L., Ruano, J., and Parra-Peralbo, E. (2022). A Scoping Review on Use of Drugs Targeting the JAK\/STAT Pathway in Psoriasis. Front. Med., 9.","DOI":"10.3389\/fmed.2022.754116"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1\/2\/3 Inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.abd.2023.03.001","article-title":"JAK-STAT Pathway Inhibitors in Dermatology","volume":"98","author":"Miot","year":"2023","journal-title":"An. Bras. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Furtunescu, A.R., Georgescu, S.R., Tampa, M., and Matei, C. (2024). Inhibition of the JAK-STAT Pathway in the Treatment of Psoriasis: A Review of the Literature. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25094681"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to Consider for the Treatment of Immune-Mediated Inflammatory Diseases with Janus Kinase Inhibitors: A Consensus Statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31138\/mjr.31.1.100","article-title":"Basic Mechanisms of JAK Inhibition","volume":"31","author":"Lin","year":"2020","journal-title":"Mediterr. J. Rheumatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and Consequences of Jak-STAT Signaling in the Immune System","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.2147\/JIR.S380686","article-title":"TYK2 in Immune Responses and Treatment of Psoriasis","volume":"15","author":"Shang","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jdv.20553","article-title":"Deucravacitinib in Plaque Psoriasis: Four-Year Safety and Efficacy Results from the Phase 3 POETYK PSO-1, PSO-2 and Long-Term Extension Trials","volume":"39","author":"Armstrong","year":"2025","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"27261","DOI":"10.1074\/jbc.M115.672048","article-title":"Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2)","volume":"290","author":"Min","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"645","DOI":"10.36849\/JDD.8293","article-title":"Selective Tyrosine Kinase 2 (TYK2) Inhibition in Plaque Psoriasis","volume":"23","author":"Kircik","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/12034754221141680","article-title":"Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway","volume":"27","author":"Loo","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4331\/wjbc.v13.i1.1","article-title":"Current Understanding of the Role of Tyrosine Kinase 2 Signaling in Immune Responses","volume":"13","author":"Muromoto","year":"2022","journal-title":"World J. Biol. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/13543776.2022.2026927","article-title":"Selective TYK2 Inhibitors as Potential Therapeutic Agents: A Patent Review (2019\u20132021)","volume":"32","author":"Guckian","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine Kinase 2 and Janus Kinase\u2014Signal Transducer and Activator of Transcription Signaling and Inhibition in Plaque Psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2154122","DOI":"10.1080\/09546634.2022.2154122","article-title":"Deucravacitinib in the Treatment of Psoriasis","volume":"34","author":"Estevinho","year":"2023","journal-title":"J. Dermatolog. Treat."},{"key":"ref_67","first-page":"1066","article-title":"Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"J. Am. Med. Assoc. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/14656566.2023.2211764","article-title":"Deucravacitinib, a Selective Tyrosine Kinase 2 Inhibitor, for the Treatment of Moderate-to-Severe Plaque Psoriasis","volume":"24","author":"Galluzzo","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/bs.mie.2022.03.051","article-title":"Identification and Characterization of TYK2 Pseudokinase Domain Stabilizers That Allosterically Inhibit TYK2 Signaling","volume":"667","author":"Locke","year":"2022","journal-title":"Methods Enzymol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"108224","DOI":"10.1016\/j.compbiolchem.2024.108224","article-title":"The Multiple-Action Allosteric Inhibition of TYK2 by Deucravacitinib: Insights from Computational Simulations","volume":"113","author":"Bao","year":"2024","journal-title":"Comput. Biol. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential Properties of Janus Kinase Inhibitors in the Treatment of Immune-Mediated Inflammatory Diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Shawky, A.M., Almalki, F.A., Abdalla, A.N., Abdelazeem, A.H., and Gouda, A.M. (2022). A Comprehensive Overview of Globally Approved JAK Inhibitors. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14051001"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1073\/pnas.1401180111","article-title":"Structure of the Pseudokinase-Kinase Domains from Protein Kinase TYK2 Reveals a Mechanism for Janus Kinase (JAK) Autoinhibition","volume":"111","author":"Lupardus","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"106642","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib Is an Allosteric TYK2 Protein Kinase Inhibitor FDA-Approved for the Treatment of Psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"104840","DOI":"10.1016\/j.ebiom.2023.104840","article-title":"Allosteric TYK2 Inhibition: Redefining Autoimmune Disease Therapy beyond JAK1-3 Inhibitors","volume":"97","author":"Jensen","year":"2023","journal-title":"EBioMedicine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.2174\/0929867330666230324163414","article-title":"Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors","volume":"31","author":"Du","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune Pathways in Mice and Humans Are Blocked by Pharmacological Stabilization of the TYK2 Pseudokinase Domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1007\/s13555-024-01262-5","article-title":"Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial","volume":"14","author":"Catlett","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.jaci.2021.11.001","article-title":"Molecular and Clinical Effects of Selective Tyrosine Kinase 2 Inhibition with Deucravacitinib in Psoriasis","volume":"149","author":"Catlett","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jid.2025.04.025","article-title":"A Triple-Action Inhibitory Mechanism of Allosteric TYK2-Specific Inhibitors","volume":"145","author":"Wang","year":"2025","journal-title":"J. Investig. Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Bang, C.-H., Park, C.-J., and Kim, Y.-S. (2025). The Expanding Therapeutic Potential of Deucravacitinib Beyond Psoriasis: A Narrative Review. J. Clin. Med., 14.","DOI":"10.3390\/jcm14051745"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in Plaque Psoriasis: 2-Year Safety and Efficacy Results from the Phase III POETYK Trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Papp, K.A., Jacobs, S., Sofen, H., Bukhalo, M., Muscianisi, E., Ma, G., Lau, G., Bettinger, M., Rubio, R.G., and Hitraya, E. (2025). Safety and Efficacy of Envudeucitinib, a Highly Selective, Oral Allosteric TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis: Results from the 52-Week Open-Label Extension Period of the Phase 2 STRIDE Study. J. Am. Acad. Dermatol.","DOI":"10.1016\/j.jaad.2025.10.005"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus Etanercept or Placebo in Moderate-to-Severe Chronic Plaque Psoriasis: A Phase 3 Randomised Non-Inferiority Trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Chronic Plaque Psoriasis: Results from Two Randomized, Placebo-Controlled, Phase III Trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40264-023-01333-0","article-title":"Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors","volume":"46","author":"Yang","year":"2023","journal-title":"Drug Saf."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.revmed.2025.06.003","article-title":"Safety Profile of JAK Inhibitors in Inflammatory or Autoimmune Diseases","volume":"46","author":"Moreau","year":"2025","journal-title":"Rev. Med. Interne"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Antonioli, L., Armuzzi, A., Fantini, M.C., and Fornai, M. (2024). JAK Inhibitors: An Evidence-Based Choice of the Most Appropriate Molecule. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1494901"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1080\/1744666X.2023.2249237","article-title":"JAK Inhibitors and Black Box Warnings: What Is the Future for JAK Inhibitors?","volume":"19","author":"Tokareva","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical Significance of Janus Kinase Inhibitor Selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The Emerging Safety Profile of JAK Inhibitors in Rheumatic Disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK Inhibition as a Therapeutic Strategy for Immune and Inflammatory Diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of Major Adverse Cardiovascular Events with Tofacitinib versus Tumour Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis with or without a History of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis from ORAL Surveillance","volume":"82","author":"Buch","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of Two Tofacitinib Subpopulations with Different Relative Risk versus TNF Inhibitors: An Analysis of the Open Label, Randomised Controlled Study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy Risk with Tofacitinib versus TNF Inhibitors in Rheumatoid Arthritis: Results from the Open-Label, Randomised Controlled ORAL Surveillance Trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_99","unstructured":"U.S. Food and Drug Administration (2025, November 26). FDA Requires Warnings about Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death."},{"key":"ref_100","unstructured":"European Medicines Agency (2025, November 26). EMA Confirms Measures to Minimise Risk of Serious Side Effects with Janus Kinase Inhibitors for Chronic Inflammatory Disorders, Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders."},{"key":"ref_101","first-page":"28","article-title":"Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis","volume":"160","author":"Ingrassia","year":"2024","journal-title":"J. Am. Med. Assoc. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in Patients with Rheumatoid Arthritis Receiving Tofacitinib versus Tumour Necrosis Factor Inhibitors: Results from the Open-Label, Randomised Controlled ORAL Surveillance Trial","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the Treatment of Psoriasis and Psoriatic Arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: First Approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Drakos, A., Torres, T., and Vender, R. (2024). Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16010111"},{"key":"ref_106","first-page":"56","article-title":"Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials","volume":"161","author":"Armstrong","year":"2025","journal-title":"J. Am. Med. Assoc. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/jdv.19925","article-title":"Deucravacitinib in Moderate-to-Severe Plaque Psoriasis: Pooled Safety and Tolerability over 52\u2009Weeks from Two Phase 3 Trials (POETYK PSO-1 and PSO-2)","volume":"38","author":"Strober","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Carmona-Rocha, E., Rusi\u00f1ol, L., and Puig, L. (2024). New and Emerging Oral\/Topical Small-Molecule Treatments for Psoriasis. Pharmaceutics, 16.","DOI":"10.20944\/preprints202401.0800.v1"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s13555-023-00977-1","article-title":"Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis","volume":"13","author":"Armstrong","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_110","unstructured":"Myers Squibb, B. (2025, November 30). Highlights of Prescribing Information, Available online: www.fda.gov\/medwatch."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/1346-8138.17685","article-title":"Deucravacitinib in plaque psoriasis: Safety and efficacy through 3 years in Japanese patients in the phase 3 POETYK PSO-1, PSO-4, and LTE trials","volume":"52","author":"Morita","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cts.13435","article-title":"First-in-human study of deucravacitinib: A selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2","volume":"16","author":"Catlett","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s13555-021-00649-y","article-title":"Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial","volume":"12","author":"Strober","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_115","first-page":"1","article-title":"Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis","volume":"27","author":"Gooderham","year":"2022","journal-title":"Skin Therapy Lett."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s13555-025-01337-x","article-title":"Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials","volume":"15","author":"Merola","year":"2025","journal-title":"Dermatol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"(2024). New Drug: Deucravacitinib for Plaque Psoriasis. Aust. Prescr., 47, 195\u2013196.","DOI":"10.18773\/austprescr.2024.049"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaad.2025.07.013","article-title":"Highly Selective, Allosteric Inhibition of TYK2 with Oral ESK-001 in Patients with Moderate-to-Severe Plaque Psoriasis: Results from STRIDE, a 12-Week, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Phase 2 Study","volume":"94","author":"Blauvelt","year":"2026","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jid.2025.05.014","article-title":"Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor","volume":"146","author":"Mehrotra","year":"2026","journal-title":"J. Investig. Dermatol."},{"key":"ref_121","first-page":"421","article-title":"Apremilast for Psoriasis Treatment","volume":"155","author":"Carrascosa","year":"2020","journal-title":"G. Ital. Di Dermatol. E Venereol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e14261","DOI":"10.1111\/dth.14261","article-title":"Apremilast in Dermatology: A Review of Literature","volume":"33","author":"Nassim","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"788","DOI":"10.36849\/JDD.8566","article-title":"Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison","volume":"24","author":"Patel","year":"2025","journal-title":"J. Drugs Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2306081","DOI":"10.1002\/adma.202306081","article-title":"Oral Nanomedicine: Challenges and Opportunities","volume":"36","author":"Deng","year":"2024","journal-title":"Adv. Mater."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/PTT.S407647","article-title":"Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature","volume":"13","author":"Potestio","year":"2023","journal-title":"Psoriasis Targets Ther."},{"key":"ref_126","first-page":"220","article-title":"Patient Preference for Dosing Frequency Based on Prior Biologic Experience","volume":"16","author":"Zhang","year":"2017","journal-title":"J. Drugs Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40257-020-00533-z","article-title":"Progress to Date in Advancing Stratified Medicine in Psoriasis","volume":"21","author":"Reid","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/PTT.S328460","article-title":"Towards Personalized Medicine in Psoriasis: Current Progress","volume":"12","author":"Camela","year":"2022","journal-title":"Psoriasis"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/ijd.70023","article-title":"A Review of Phase III and Long-Term Data for Deucravacitinib for Plaque Psoriasis","volume":"65","author":"Babaei","year":"2026","journal-title":"Int. J. Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Qiu, J., Liu, J., Liu, W., Lin, F., and Shi, N. (2023). The Efficacy and Safety of Tyrosine Kinase 2 Inhibitor Deucravacitinib in the Treatment of Plaque Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1264667"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"590","DOI":"10.25259\/IJDVL_775_2023","article-title":"Comparative Efficacy and Safety of JAK\/TYK2 Inhibitors and Other Oral Drugs for Moderate-to-Severe Plaque Psoriasis: Systematic Review and Network Meta-Analysis","volume":"90","author":"Zheng","year":"2024","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s11096-025-01896-1","article-title":"Real-World Safety of Deucravacitinib: Insights from the Food and Drug Administration Adverse Event Reporting System","volume":"47","author":"Zhao","year":"2025","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_134","first-page":"101","article-title":"Pharmacological Management of Psoriasis: Current Landscape and Future Perspectives","volume":"20","author":"Pedwar","year":"2025","journal-title":"Recent Adv. Inflamm. Allergy Drug Discov."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2025.09.036","article-title":"Novel TYK2 Inhibitor D-2570 in Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"94","author":"Zhang","year":"2026","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12964-023-01299-7","article-title":"A Novel Highly Selective Allosteric Inhibitor of Tyrosine Kinase 2 (TYK2) Can Block Inflammation- and Autoimmune-Related Pathways","volume":"21","author":"Chen","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"103649","DOI":"10.1016\/j.autrev.2024.103649","article-title":"Tyrosine Kinase 2 Inhibitors in Autoimmune Diseases","volume":"23","author":"Ramakrishna","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"103723","DOI":"10.1016\/j.autrev.2024.103723","article-title":"Deucravacitinib Shows Superior Efficacy and Safety in Cutaneous Lupus Erythematosus Compared to Various Biologics and Small Molecules - A Systematic Review and Meta-Analysis","volume":"24","author":"Bokor","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/bjd\/ljaf293","article-title":"Tyrosine Kinase 2 Inhibition Improves Clinical and Molecular Hallmarks in Subtypes of Cutaneous Lupus","volume":"193","author":"Wasserer","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and Safety of Selective TYK2 Inhibitor, Deucravacitinib, in a Phase II Trial in Psoriatic Arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Martins, A., L\u00e9, A.M., and Torres, T. (2023). Deucravacitinib for the Treatment of Psoriatic Arthritis: The Evidence so Far. Drugs Context, 12.","DOI":"10.7573\/dic.2023-2-7"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1093\/rheumatology\/keae580","article-title":"Deucravacitinib, a Selective, TYK2 Inhibitor, in Psoriatic Arthritis: Achievement of Minimal Disease Activity Components in a Phase 2 Trial","volume":"64","author":"Kavanaugh","year":"2025","journal-title":"Rheumatology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"jjaf080","DOI":"10.1093\/ecco-jcc\/jjaf080","article-title":"Deucravacitinib in Patients with Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results from 3 Randomized Phase 2 Studies in Crohn\u2019s Disease and Ulcerative Colitis","volume":"19","author":"Danese","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"e001517","DOI":"10.1136\/lupus-2025-001517","article-title":"Deucravacitinib, an Oral, Selective, Allosteric, Tyrosine Kinase 2 Inhibitor, in Patients with Active SLE: Efficacy on Patient-Reported Outcomes in a Phase II Randomised Trial","volume":"12","author":"Mosca","year":"2025","journal-title":"Lupus Sci. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1759720X211014010","DOI":"10.1177\/1759720X211014010","article-title":"Biomarkers Predictive of Treatment Response in Psoriasis and Psoriatic Arthritis: A Systematic Review","volume":"13","author":"Magee","year":"2021","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 Genotype Is a Predictive Biomarker of Biologic Treatment Response in Psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/bjd.21677","article-title":"Biomarkers of Systemic Treatment Response in People with Psoriasis: A Scoping Review","volume":"187","author":"Corbett","year":"2022","journal-title":"Br. J. Dermatol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/3\/347\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:42:43Z","timestamp":1773380563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/3\/347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":148,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["pharmaceutics18030347"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18030347","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}